Compare RDCM & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDCM | CNTN |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.2M | 146.5M |
| IPO Year | 1999 | 2021 |
| Metric | RDCM | CNTN |
|---|---|---|
| Price | $10.39 | $2.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | 189.4K | ★ 700.3K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $1.75 |
| 52 Week High | $16.74 | $5.27 |
| Indicator | RDCM | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 34.80 | 44.48 |
| Support Level | $9.40 | $1.75 |
| Resistance Level | $13.27 | $3.80 |
| Average True Range (ATR) | 0.45 | 0.13 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 27.38 | 77.94 |
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.